CN101970431A - 用作治疗化合物的取代哌啶 - Google Patents

用作治疗化合物的取代哌啶 Download PDF

Info

Publication number
CN101970431A
CN101970431A CN2009801083136A CN200980108313A CN101970431A CN 101970431 A CN101970431 A CN 101970431A CN 2009801083136 A CN2009801083136 A CN 2009801083136A CN 200980108313 A CN200980108313 A CN 200980108313A CN 101970431 A CN101970431 A CN 101970431A
Authority
CN
China
Prior art keywords
methyl
compound
straight chain
methoxyl group
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801083136A
Other languages
English (en)
Chinese (zh)
Inventor
P·赫罗德
R·马
S·斯图兹
V·茨恩克
A·斯托亚诺维克
D·本克
S·耶拉克维克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN101970431A publication Critical patent/CN101970431A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2009801083136A 2008-04-02 2009-04-01 用作治疗化合物的取代哌啶 Pending CN101970431A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08153929 2008-04-02
EP08153929.8 2008-04-02
PCT/EP2009/053898 WO2009121914A1 (en) 2008-04-02 2009-04-01 Substituted piperidines as therapeutic compounds

Publications (1)

Publication Number Publication Date
CN101970431A true CN101970431A (zh) 2011-02-09

Family

ID=40627638

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801083136A Pending CN101970431A (zh) 2008-04-02 2009-04-01 用作治疗化合物的取代哌啶

Country Status (10)

Country Link
EP (1) EP2271644A1 (pt)
JP (1) JP2011516453A (pt)
KR (1) KR20110002459A (pt)
CN (1) CN101970431A (pt)
AU (1) AU2009232012A1 (pt)
BR (1) BRPI0910991A2 (pt)
CA (1) CA2719070A1 (pt)
EA (1) EA201001517A1 (pt)
MX (1) MX2010010876A (pt)
WO (1) WO2009121914A1 (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105001300A (zh) * 2014-04-17 2015-10-28 复旦大学 组织蛋白酶d抑制剂及其制备方法、药物组合物和应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011057160A2 (en) * 2009-11-06 2011-05-12 The Regents Of The Uiversity Of California Method to improve the immunogenicity of vaccine antigens by modification of cleavage sites in hiv-1 gp 120
CN102638981B (zh) 2009-10-14 2015-07-22 默沙东公司 提高p53活性的取代的哌啶和其用途
GB201008209D0 (en) * 2010-05-17 2010-06-30 Senexis Ltd Compounds
US8987274B2 (en) 2011-10-28 2015-03-24 Merck Sharp & Dohme Corp Macrocycles that increase p53 activity and the uses thereof
TW201429969A (zh) 2012-12-20 2014-08-01 Merck Sharp & Dohme 作爲ｈｄｍ２抑制劑之經取代咪唑吡啶

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1816122A3 (en) * 2006-01-19 2007-09-19 Speedel Experimenta AG 3,4,5-substituted piperidines as therapeutic compounds
EP1911758A1 (en) * 2006-10-04 2008-04-16 Speedel Experimenta AG Phenyl piperidine derivatives for use as renin inhibitors
EP1908761A1 (en) * 2006-10-04 2008-04-09 Speedel Experimenta AG Organic compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105001300A (zh) * 2014-04-17 2015-10-28 复旦大学 组织蛋白酶d抑制剂及其制备方法、药物组合物和应用

Also Published As

Publication number Publication date
EA201001517A1 (ru) 2011-04-29
AU2009232012A1 (en) 2009-10-08
KR20110002459A (ko) 2011-01-07
BRPI0910991A2 (pt) 2016-01-19
EP2271644A1 (en) 2011-01-12
CA2719070A1 (en) 2009-10-08
MX2010010876A (es) 2010-10-26
WO2009121914A1 (en) 2009-10-08
JP2011516453A (ja) 2011-05-26

Similar Documents

Publication Publication Date Title
ES2892954T3 (es) Derivados fluorados del ácido 3-(2-oxo-3-(3-(5,6,7,8-tetrahidro-1,8-naftiridin-2-il)propil)imidazolidin-1-il)propanoico y usos de los mismos
CN101970431A (zh) 用作治疗化合物的取代哌啶
TWI472329B (zh) 埃坡徽素ｄ於治療包括阿茲海默症之ｔａｕ相關疾病的用途
JP2013528160A (ja) 抗インフルエンザ活性を有するザナミビルホスホネート同族体およびインフルエンザウイルスのオセルタミビルに対する感受性の決定
RU2758256C2 (ru) Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок
BR112019019928A2 (pt) derivados de indolina substituídos como inibidores da replicação viral da dengue
CN103239720A (zh) 治疗或缓解疼痛的物质
CA3017028C (en) Fibrotic treatment
CN103958521A (zh) 嘧啶-4-酮衍生物及其在治疗、减轻或预防病毒疾病中的用途
CN103387601B (zh) 抗登革热病毒(denv)杂环肽类化合物及其制备方法和用途
CN101410378B (zh) 作为γ分泌酶抑制剂的丙二酰胺衍生物
CN101100416B (zh) 阻止阿尔茨海默氏症Aβ多肽纤维化的小分子抑制剂及其制备方法、药物组合物和应用
TWI832450B (zh) 肌酸前藥、組合物及其使用方法
US8765953B2 (en) Compounds and methods for the treatment of pain and other diseases
CN103917093A (zh) 视蛋白结合配体、组合物及使用方法
JPWO2009096455A1 (ja) 脂肪性肝疾患の治療用医薬組成物
TW202309038A (zh) sGC刺激劑
TW202308634A (zh) 使用sGC刺激劑之CNS疾病治療
CN111253412B (zh) α-倒捻子素衍生物及其应用
WO2019117812A1 (en) Near infra-red molecular probes for use in diagnosis of fibrotic conditions and screening of anti-fibrotic drugs
CN101535282A (zh) 3-苄基-2-甲基-2，3，3a，4，5，6，7，7a-八氢苯并[d]异噁唑-4-酮的盐
EP1867329A2 (en) 5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonanamides as therapeutic compounds
CN101415703A (zh) 用作肾素抑制剂的取代的4-苯基哌啶
TW200400971A (en) Par-2-activating peptide derivative and pharmaceutical composition using the same
KR20120118014A (ko) 항응고제 화합물 및 그의 용도

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20110209